Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Boston Scientific Corporation's third-quarter performance highlights significant growth, driven chiefly by its Cardiovascular segment, particularly in Electrophysiology (EP) and the WATCHMAN product line.</li><li>The company's operational sales ascended by 19%, with organic sales rising by 15%, both exceeding forecasted ranges.</li><li>This robust performance underscores Boston Scientific's strategic focus and execution prowess.</li></ul>

Boston Scientific Corporation's third-quarter performance highlights significant growth, driven chiefly by its Cardiovascular segment, particularly in Electrophysiology (EP) and the WATCHMAN product line.The company's operational sales ascended by 19%, with organic sales rising by 15%, both exceeding forecasted ranges.This robust performance underscores Boston Scientific's strategic focus and execution prowess.

Boston Scientific: Inside China’s Explosive MedTech Boom!

<ul><li>Boston Scientific Corporation delivered robust financial results in the second quarter of 2025, exceeding both market expectations and its own guidance.</li><li>The company reported operational sales growth of 22% and organic sales growth of 17%, surpassing its forecasted range of 13% to 15%.</li><li>Adjusted earnings per share (EPS) increased by 23% to $0.75, also exceeding expectations.</li></ul>

Boston Scientific Corporation delivered robust financial results in the second quarter of 2025, exceeding both market expectations and its own guidance.The company reported operational sales growth of 22% and organic sales growth of 17%, surpassing its forecasted range of 13% to 15%.Adjusted earnings per share (EPS) increased by 23% to $0.75, also exceeding expectations.

Boston Scientific in MedSurg: Will Double-Digit Growth Silence Competitors?

<ul><li>Boston Scientific Corporation reported strong first quarter 2025 results, exhibiting significant growth in both revenue and earnings.</li><li>The company's total operational sales increased by 22% while organic sales grew by 18%, surpassing the upper range of guidance of 14% to 16%.</li><li>In terms of earnings, the first quarter adjusted EPS reached $0.75, a 34% growth over the previous year, exceeding the projected range of $0.66 to $0.68.</li></ul>

Boston Scientific Corporation reported strong first quarter 2025 results, exhibiting significant growth in both revenue and earnings.The company's total operational sales increased by 22% while organic sales grew by 18%, surpassing the upper range of guidance of 14% to 16%.In terms of earnings, the first quarter adjusted EPS reached $0.75, a 34% growth over the previous year, exceeding the projected range of $0.66 to $0.68.

Boston Scientific WATCHMAN Surge: Will 20% Growth & New Clinical Data Cement Its Cardiovascular Dominance?

<ul><li>The financial results for Boston Scientific's fourth quarter and full-year 2024 highlight both strengths and challenges faced by the company.</li><li>Achieving robust growth in several segments, the company reported operational sales growth of 23% for the quarter and 18.5% for the year, with organic growth hitting 20% and 16% respectively.</li><li>These figures surpass their upper guidance limits, indicating strong market performance, driven primarily by the early U.S. adoption of the FARAPULSE system and other key products.</li></ul>

The financial results for Boston Scientific's fourth quarter and full-year 2024 highlight both strengths and challenges faced by the company.Achieving robust growth in several segments, the company reported operational sales growth of 23% for the quarter and 18.5% for the year, with organic growth hitting 20% and 16% respectively.These figures surpass their upper guidance limits, indicating strong market performance, driven primarily by the early U.S. adoption of the FARAPULSE system and other key products.

Boston Scientific: How WATCHMAN and FARAPULSE Expansion Is Shaping This Med-Tech Giant’s Future!

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medtronic-plc" target="_blank" data-smartkarma-citation="entities:14982:1" rel="noopener">Medtronic Plc (MDT US)</a> reported Q2FY24 revenue of $8B, representing 5% organic growth, topping guidance of 4.0–4.5%. Cardiovascular, neuroscience, and medical surgical grew mid-single-digit with diabetes accelerating to high-single-digit.</li>
<li>The company now expects FY24 organic revenue growth of 4.75% versus the prior 4.5%. Medtronic raised FY24 adjusted EPS guidance to $5.13–5.19 from $5.08–5.16 earlier.</li>
<li>In November, the company has received FDA approval for innovative renal denervation device for the treatment of hypertension, which should open a multi-billion-dollar market opportunity.</li>
</ul>



Medtronic Plc (MDT US) reported Q2FY24 revenue of $8B, representing 5% organic growth, topping guidance of 4.0–4.5%. Cardiovascular, neuroscience, and medical surgical grew mid-single-digit with diabetes accelerating to high-single-digit.
The company now expects FY24 organic revenue growth of 4.75% versus the prior 4.5%. Medtronic raised FY24 adjusted EPS guidance to $5.13–5.19 from $5.08–5.16 earlier.
In November, the company has received FDA approval for innovative renal denervation device for the treatment of hypertension, which should open a multi-billion-dollar market opportunity.


Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

United States

Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology and neuromodulation.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Boston Scientific (BSX US)

Boston Scientific: Inside China’s Explosive MedTech Boom!

Boston Scientific Corporation's third-quarter performance highlights significant growth, driven chiefly by its Cardiovascular segment,...

Baptista Research

Boston Scientific in MedSurg: Will Double-Digit Growth Silence Competitors?

Boston Scientific Corporation delivered robust financial results in the second quarter of 2025, exceeding both market expectations and its own...

Baptista Research

Boston Scientific WATCHMAN Surge: Will 20% Growth & New Clinical Data Cement Its Cardiovascular Dominance?

Boston Scientific Corporation reported strong first quarter 2025 results, exhibiting significant growth in both revenue and earnings. The...

Baptista Research

Boston Scientific: How WATCHMAN and FARAPULSE Expansion Is Shaping This Med-Tech Giant’s Future!

The financial results for Boston Scientific's fourth quarter and full-year 2024 highlight both strengths and challenges faced by the...

Baptista Research

Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Boston Scientific: Inside China’s Explosive MedTech Boom!

Boston Scientific Corporation's third-quarter performance highlights significant growth, driven chiefly by its Cardiovascular segment,...

Baptista Research

Boston Scientific in MedSurg: Will Double-Digit Growth Silence Competitors?

Boston Scientific Corporation delivered robust financial results in the second quarter of 2025, exceeding both market expectations and its own...

Baptista Research

Boston Scientific WATCHMAN Surge: Will 20% Growth & New Clinical Data Cement Its Cardiovascular Dominance?

Boston Scientific Corporation reported strong first quarter 2025 results, exhibiting significant growth in both revenue and earnings. The...

Baptista Research

Boston Scientific: How WATCHMAN and FARAPULSE Expansion Is Shaping This Med-Tech Giant’s Future!

The financial results for Boston Scientific's fourth quarter and full-year 2024 highlight both strengths and challenges faced by the...

Baptista Research

Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

​Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...

Tina Banerjee

Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...